Person:
AKYÜZ, GÜLSEREN DERYA

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

AKYÜZ

First Name

GÜLSEREN DERYA

Name

Filters

2003 - 200912010 - 20152
Reset filters

Settings

Has files: true × Subject: VERTEBRAL FRACTURES ×

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    PublicationOpen Access
    Fracture History in Osteoporosis: Risk Factors and its Effect on Quality of Life
    (AVES, 2015-01-15) AKYÜZ, GÜLSEREN DERYA; Kuru, Pinar; Akyuz, Gulseren; Cersit, Hulya Peynirci; Celenlioglu, Alp Eren; Cumhur, Ahmet; Biricik, Sefikcan; Kozan, Seda; Goksen, Aylin; Ozdemir, Mikail; Luleci, Emel
    Background: Fractures are one of the main outcomes in osteoporosis and have an important effect on the general health status. Aims: The purpose of this study was to determine the effect of major fracture history on quality of life. We also investigated the important risk factors and their effect on bone mineral density and fracture history. Study Design: Cross-sectional study. Methods: We recruited 105 patients who were admitted to an osteoporosis outpatient clinic. Medical history, family history, calcium intake, physical activity level and biochemical tests were evaluated. Lumbar spine and femur neck bone mineral density were measured. The Qualeffo-41 questionnaire was also used for evaluating quality of life. Results: The average age of the 105 patients included in the study was 56.04 +/- 13.73 and 89% of them were post-menopausal women. The average body mass index was 26.84 +/- 5.99, which means that the women were overweight. Also, 48.5% of the patients were diagnosed with osteoporosis and 51.5% of them were diagnosed as low bone density. A total of 34 patients had a fracture history with minor trauma and some of the patients had more than one fracture (12 ankle and foot, 10 forearm, 9 vertebral, 4 hand, 3 hip, 2 rib, 1 tibial). When the patients with and without fracture history were compared, the mean Qualeffo-41 score in patients with fracture was 43.85 +/- 2.57 and in the non-fracture group was 36.27 +/- 2.01. Conclusion: Forearm, ankle and foot fractures can be commonly seen in osteoporosis patients with fracture history. We suggest that it is important to recognise osteoporosis prior to first fracture and disease-specific quality of life assessment should be done.
  • Thumbnail Image
    PublicationOpen Access
    Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis
    (YONSEI UNIV COLL MEDICINE, 2003) AKYÜZ, GÜLSEREN DERYA; Aki, S; Eskiyurt, N; Akarirmak, U; Tuzun, F; Eryavuz, M; Alper, S; Arpacioglu, O; Atalay, F; Kavuncu, V; Kokino, S; Kuru, O; Nas, K; Ozerbil, O; Savas, G; Sendur, OF; Soy, D; Akyuz, G
    The aim of our study was to evaluate the upper gastrointestinal (GI) tract side effect profile in 759 female patients that had taken alendronate (10 mg/day), for at least 6 months, for the treatment of osteoporosis, in relation to the safety of alendronate and the compliance of patients to its absorption rules. This study was a multicentered retrospective, clinical, non-placebo controlled, study of 759 female subjects carried out at 26 centres in 6 different regions of Turkey. The mean age of our patients was 62.6 +/- 8.6, with 51.2% in the age range 60 to 69 years. 158 patients (20.8%) were considered to have upper GI tract complaints with nausea as the most often encountered symptom. Of the subjects with upper GI tract complaints, 20% reported discontinued drug use, and 30% reported the requirement of an additional drug in order to abolish their complaints. Approximately 537 (71%) of the patients stated they had been given written information about the administration of the drug, and at least 93 patients (12%) and 73 patients (18.4%) acknowledged non compliance with the safety and absorption rules, respectively. In our study, no significant difference was found between the adherence to the safety measures and upper GI tract complaints (p>0.05), but that upper GI tract complaints were higher in patients taking additional medication to alendronate (p<0.05).
  • Thumbnail Image
    PublicationOpen Access
    Impact of the Training on the Compliance and Persistence of Weekly Bisphosphonate Treatment in Postmenopausal Osteoporosis: A Randomized Controlled Study
    (IVYSPRING INT PUBL, 2013) AKYÜZ, GÜLSEREN DERYA; Tuzun, Sansin; Akyuz, Gulseren; Eskiyurt, Nurten; Memis, Asuman; Kuran, Banu; Icagasioglu, Afitap; Sarpel, Tunay; Ozdemir, Ferda; Ozgirgin, Nese; Gunaydin, Rezzan; Cakci, Aytul; Yurtkuran, Merih
    Long-term patient adherence to osteoporosis treatment is poor despite proven efficacy. In this study, we aimed to assess the impact of active patient training on treatment compliance and persistence in patients with postmenopausal osteoporosis. In the present national, multicenter, randomized controlled study, postmenopausal osteoporosis patients (45-75 years) who were on weekly bisphosphonate treatment were randomized to active training (AT) and passive training (PT) groups and followed-up by 4 visits after the initial visit at 3 months interval during 12 months of the treatment. Both groups received a bisphosphonate usage guide and osteoporosis training booklets. Additionally, AT group received four phone calls (at 2nd, 5th, 8th, and 11th months) and participated to four interactive social/training meetings held in groups of 10 patients (at 3rd, 6th, 9th, and 12th months). The primary evaluation criteria were self-reported persistence and compliance to the treatment and the secondary evaluation criteria was quality life of the patients assessed by 41-item Quality of Life European Foundation for Osteoporosis (QUALEFFO-41) questionnaire.. Of 448 patients (mean age 62.4 +/- 7.7 years), 226 were randomized to AT group and 222 were randomized to PT group. Among the study visits, the most common reason for not receiving treatment regularly was forgetfulness (54.9% for visit 2, 44.3% for visit 3, 51.6% for visit 4, and 43.8% for visit 5), the majority of the patients always used their drugs regularly on recommended days and dosages (63.8% for visit 2, 60.9% for visit 3, 72.1% for visit 4, and 70.8% for visit 5), and most of the patients were highly satisfied with the treatment (63.4% for visit 2, 68.9% for visit 3, 72.4% for visit 4, and 65.2% for visit 5) and wanted to continue to the treatment (96.5% for visit 2, 96.5% for visit 3, 96.9% for visit 4, and 94.4% for visit 5). QUALEFFO scores of the patients in visit 1 significantly improved in visit 5 (37.7 +/- 25.4 vs. 34.0 +/- 14.6, p<0.001); however, the difference was not significant between AT and PT groups both in visit 1 and visit 5. In conclusion, in addition to active training, passive training provided at the 1st visit did not improve the persistence and compliance of the patients for bisphosphonate treatment.